Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy
Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy
This is a multi-center, long-term safety and efficacy follow-up study for subjects with
 sickle cell disease who have been treated with ex vivo gene therapy drug product in bluebird
 bio-sponsored clinical studies. After completing the parent clinical study (approximately 2
 years), eligible subjects will be followed for an additional 13 years for a total of 15 years
 post-drug product infusion. No investigational drug product will be administered in the
 study.
Inclusion Criteria:

 -  Provision of written informed consent for this study by subject, or as applicable,
 subject's parent(s)/legal guardian(s)

 -  Treated with drug product for therapy of sickle cell disease in a bluebird
 bio-sponsored clinical study

 -  Able to comply with study requirements

 Exclusion Criteria:

 -  There are no exclusion criteria for this study